Mutations to kirromycin resistance occur in the interface of domains I and III of EF‐Tu·GTP
- 26 September 1994
- journal article
- Published by Wiley in FEBS Letters
- Vol. 352 (2) , 118-122
- https://doi.org/10.1016/0014-5793(94)00937-6
Abstract
The antibiotic kirromycin inhibits protein synthesis by binding to EF‐Tu and preventing its release from the ribosome after GTP hydrolysis. We have isolated and sequenced a collection of kirromycin resistant tuf mutations and identified thirteen single amino acid substitutions at seven different sites in EF‐Tu. These have been mapped onto the 3D structures of EF‐Tu·GTP and EF‐Tu·GDP. In the active GTP form of EF‐Tu the mutations cluster on each side of the interface between domains I and III. We propose that this domain interface is the binding site for kirromycin.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of the complete sequence of the str operon in Salmonella typhimurium and Escherichia coliGene, 1992
- Refined structure of elongation factor EF-Tu from Escherichia coliJournal of Molecular Biology, 1992
- Missense substitutions lethal to essential functions of EF-TuBiochimie, 1991
- Kirromycin drastically reduces the affinity of Escherichia coli elongation factor Tu for aminoacyl-tRNABiochemistry, 1991
- Impaired in vitro kinetics of EF‐Tu mutant AaEuropean Journal of Biochemistry, 1990
- Antisuppression by mutations in elongation factor TuEuropean Journal of Biochemistry, 1990
- Mutant forms of tufA and tufB independently suppress nonsense mutationsJournal of Molecular Biology, 1987
- MECHANISM OF ACTION OF KIRROMYCIN-LIKE ANTIBIOTICSAnnual Review of Microbiology, 1985
- Identification of the part of kirromycin structure that acts on elongation factor TuFEBS Letters, 1981
- The role of guanosine 5′-triphosphate in polypeptide chain elongationBiochimica et Biophysica Acta (BBA) - Reviews on Bioenergetics, 1978